Medical Specialty >> Oncology
HealthDay Reporter Read article
- Doctors Aren’t Promoting Breastfeeding’s Cancer-Protection Benefit
- Mammograms Do Save Lives: Study
- The Bigger the Brain, the Bigger the Tumor Risk?
- HPV Vaccination Rates Continue to Lag in U.S.
- Genetic Test Helps ID Benign Versus Malignant Thyroid Nodules
- Income, Lifestyle May Contribute to Disparity in Cancer Deaths
- Improved Long-Term Pregnancy Outcomes for Goserelin + Chemo
Robert L. Coleman, MD. Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of… Elizabeth M. Swisher, MD. Dr. Elizabeth M. Swisher comments on the implications of new data from the ARIEL2 trial, an ongoing Phase 2 trial of the novel PARP inhibitor rucaparib in relapsed, high-grade serous or endometrioid ovarian cancer. The new results offer an important insight into the genetic mechanisms behind tumor sensitivity… Bert Vogelstein, MD. Investigators at Johns Hopkins University in Baltimore used complex mathematical modeling to track mutations driving abnormal cell growth for 32 types of cancer. From their calculations, the researchers believe that the bulk of cancers are caused by random DNA copying errors (replicative mutations).…
Great articles. learnt a lot from it.